An experimental drug has restored memory and learning in mice that were already showing severe signs of Alzheimer’s disease.
By bringing a crucial energy molecule in brain cells back to healthy levels, the treatment suggests that even advanced mental decline may not be permanent.
Memory came back
In tests that measure recognition and navigation, treated mice performed like healthy animals again after symptoms had set in.
Using those readouts, Andrew A. Pieper, M.D., Ph.D., at Case Western Reserve University (CWRU) traced the recovery to restored brain chemistry.
Pieper watched late-stage animals regain cognitive skills, a result that challenges the belief that advanced decline only moves one way.
That reversal made the team look for a shared weakness inside stressed neurons, rather than chasing each symptom separately.
An energy reset
Inside neurons, the team focused on NAD+, a helper molecule that moves energy, and it often drops with age.
The experimental drug helped the brain keep that molecule in a normal range, instead of letting it crash during disease.
After six months of daily injections, NAD+ levels returned to normal in mice that already showed advanced symptoms.
Keeping that fuel supply steady also lowered signs of cell stress, suggesting that energy balance can steady many systems at once.
Plaques were not fate
Autopsies often reveal plaques and tangles in Alzheimer’s disease, and the mouse brains carried similar buildups.
In one model, amyloid-beta, a protein fragment that clumps between neurons, stayed abundant even as behavior improved on memory tasks.
Across the tau-based model, tau, a nerve-cell protein that can twist into tangles, also changed form while cognition recovered.
That outcome left a hard message, neurons can regain function even when classic protein debris remains in the background.
Barrier walls recovered
Leakiness in the blood-brain barrier, the filter that controls brain entry, eased after the experimental drug restored vessel linings.
Microscope images showed tighter seals and less immune leakage, changes that can cut inflammation inside delicate brain tissue.
When human endothelial cells, cells that line tiny brain vessels, faced oxidative damage in dishes, the experimental drug protected them.
Stronger vessel walls may have helped the drug reach neurons safely, while also limiting outside signals that worsen symptoms.
Inflammation calmed down
Markers of neuroinflammation, immune activity that irritates brain cells, dropped after treatment in the mice with advanced symptoms.
Activated support cells quieted, and the data linked that change to steadier NAD+ that left fewer distress signals.
Levels tied to oxidative stress, chemical wear that damages fats and proteins, also fell after months of dosing.
Reducing those stressors mattered because they can scramble synapses, the connections that let brain circuits store memories.
Human brains matched
Human brain samples showed about a 30% drop in NAD+ compared with controls, matching worse damage across many measures.
In those tissues, lower NAD+ lined up with more tau injury, more oxidative damage, and weaker blood vessel protections.
A summary captured Pieper’s view that restoring brain energy can support recovery, even when symptoms look entrenched.
“The damaged brain can, under some conditions, repair itself and regain function,” says Pieper.
Cancer risk matters
High-dose supplementation that drives NAD+ far above normal has raised cancer concerns in prior lab and animal work.
The experimental drug aimed for homeostasis, keeping levels in a healthy range, rather than pushing NAD+ past what brain cells can handle.
Safety still needs real testing, because a drug that touches basic metabolism can affect organs beyond the brain.
Until that work happens, no one should treat these mouse results as a reason to self-dose with NAD boosters.
Hard steps to humans
Mouse models capture only slices of Alzheimer’s, so success in engineered animals cannot predict how older human brains will respond.
Most people develop the disease slowly, with many risk factors mixing, and the mice used single genetic drivers.
Daily dosing for months in a mouse compresses years of illness in people, which complicates planning human trials.
Carefully designed clinical studies will need to watch thinking, mood, and side effects at the same time, not separately.
Clues for future drugs
Beyond behavior, CWRU researchers mapped dozens of brain proteins that moved back toward normal when NAD+ balance returned.
In a cross-species comparison, 46 proteins changed in similar directions in mice and in human Alzheimer tissue.
Those shared signals could guide drug design and also help track whether a future therapy truly repairs brain function.
Finding consistent markers also sets a higher bar, because a treatment that only helps symptoms would not reset those deeper changes.
Hope needs guardrails
Rebuilding NAD+ balance lets the drug touch memory, vessel health, and inflammation at once, even in advanced disease.
“The key takeaway is a message of hope: the effects of Alzheimer’s disease may not be inevitably permanent,” says Pieper.
The study is published in Cell Reports Medicine.
